HUGE News and Press, FSD Pharma Inc. From 11/30/20

Sunesis Pharmaceuticals (SNSS) +50% after announcing merger agreement with Viracta Therapeutics.China Automotive Systems (CAAS) +32% on guiding 2021 sales boom.India Globalization Capital (IGC) +24%.Ameri Holdings (AMRH) +26%.Oramed Pharmaceuticals (ORMP) +24%.Navios ...

FSD Pharma (HUGE): Q3 net loss of $18MShares -2.15% AH.Press Release For further details see: FSD Pharma reports Q3 results

FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (“FSD Pharma” or the “Company”) today announced its financial results for the third quarter ending September 30, 2020 and provided a corporate update. The filing is available on SEDAR. Financial and corporate hig...

FTS International (FTSI) +67% after successful confirmation of plan of reorganization.Mogo (MOGO) +58% after announcing MogoSpend supports Apple Pay, Google Pay and Samsung Pay.GoPro (GPRO) +21% on Q3 results.Glu Mobile (GLUU) +17% on Q3 results.Aurora ...

FSD Pharma Inc. (Nasdaq: HUGE) (“FSD Pharma” or the “Company”), today announced the closing of previously announced definitive agreements with investors for the purchase and sale of 4,318,179 Class B Subordinate Voting Shares of the Company (“Shares&#x...

Gainers: ReWalk Robotics (RWLK) +18%, Aldeyra Therapeutics (ALDX) +19%, ClearPoint Neuro (CLPT) +15%, ProPhase Labs (PRPH) +12%, Orchard Therapeutics (ORTX) +11%.Losers: Biomerica (BMRA) -20%, Adaptimmune Therapeutics (ADAP) -14%, Ca...

FSD Pharma (HUGE) to sell 4,318,179 Class B subordinate voting shares of the company and warrants to purchase 3,454,543 shares at $2.20/share in a registered direct offering.The warrants exercisable immediately at $2.60 /share and will expire five years from the date of issuance.Offering...

FSD Pharma Inc. (Nasdaq: HUGE) (“FSD Pharma” or the “Company”), today announced that it has entered into definitive agreements with investors for the purchase and sale of 4,318,179 Class B Subordinate Voting Shares of the Company (“Shares”) and ...

Nano cap FSD Pharma (HUGE) perks up 7% premarket on average volume in response to the initiation of a 352-subject Phase 2 clinical trial evaluating orally available FSD201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA), along with standard-of-care ((SOC)) treat...

MyoKardia (MYOK) +59% as Bristol to acquire the company for $225/Share.Kosmos Energy (KOS) +50% as company closed a Gulf of Mexico facility with Beal Bank USA and Trafigura Trading LLC.Enlivex Therapeutics (ENLV) +49%.Corvus Pharmaceuticals (CRVS) +38% on co-foun...